Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

January 14, 2020

Study Completion Date

January 14, 2020

Conditions

Diabetic Neuropathy Peripheral

Interventions

DRUG

25mg

SYHA1402 25mg or Placebo 25mg

DRUG

50mg

SYHA1402 50mg or Placebo 50mg

DRUG

100mg

SYHA1402 100mg or Placebo 100mg

DRUG

200mg

SYHA1402 200mg or Placebo 200mg

DRUG

400mg

SYHA1402 400mg or Placebo 400mg

DRUG

800mg

SYHA1402 800mg or Placebo 800mg

Trial Locations (1)

The General Hospital of the People's Liberation Army, Beijing

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT03988413 - Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People | Biotech Hunter | Biotech Hunter